Nedaplatin-NSC-375101D-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemENedaplatinCat. No.: HY-13700CAS No.: 95734-82-0Synonyms: NSC 375101D分式: CHNOPt分量: 303.18作靶點: DNA/RNA Synthesis作通路: Cell Cycle/DNA Damage儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 H2O : 13.6 m

2、g/mL (44.86 mM; Need ultrasonic and warming; DMSO can inactivate Nedaplatins activity)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.2984 mL 16.4919 mL 32.9837 mL5 mM 0.6597 mL 3.2984 mL 6.5967 mL10 mM 0.3298 mL 1.6492 mL 3.2984 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY

3、物活性 Nedaplatin (NSC 375101D)鉑衍物和DNA損傷劑。體外研究Nedaplatin (NSC 375101D, NDP) is a derivative of cisplatin which produced less nausea & vomiting andnephrotoxicity. the effect of NDP on the 7-ethyl-1-hydroxy-CPT (the active form of CPT-11)-induced inhibitoryeffect on DNA topoisomerase I was examined. The

4、topoisomerase I-inhibitory effect of 7-ethyl-1-hydroxy-CPT was enhanced 10-fold in the presence of Nedaplatin (NSC 375101D, NDP) at microgram/milliliter1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEconcentrations 1. Nedaplatin (NSC 375101D, NDP) was developed as a second generation platinumcomple

5、x. Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP). At thehigh-dose of Nedaplatin (NSC 375101D, NDP) in FN therapy, a reduction of tumour size and long-termtumour-free survival were frequently observed. The survival effect of the combinations of Nedaplatin (

6、NSC375101D, NDP) with 5-FU was superior to those of the combination of CDDP with 5-FU. In conclusion, thesequence-dependent antitumour efficacy and toxicity of the combination of NDP or CDDP with 5-FU wasdemonstrated in this study, and FN therapy appeared to be the most efficient regimen as a clinic

7、al therapy2.REFERENCES1. Kanzawa, F., et al., In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitoririnotecan and the mechanism of this interaction. Clin Cancer Res, 2001. 7(1): p. 202-9.2. Uchida, N., et al., Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with5-fluorouracil in an in vivo murine tumour model. Eur J Cancer, 1998. 34(11): p. 1796-801.McePdfHeightCaution: Product has not been fully validated for medical applications.For r